Detirelix

Summary

Detirelix is a synthetic decapeptide that acts as a gonadotropin‑releasing hormone (GnRH) antagonist. In research settings it has been used to suppress pituitary secretion of luteinising hormone (LH) and follicle‑stimulating hormone (FSH), thereby reducing downstream sex steroids such as estradiol and testosterone. Studies in women, post‑menopausal volunteers, free‑ranging African elephants and sheep have demonstrated its ability to block gonadotropin release, inhibit follicular development and prevent ovulation, with effects that reverse after the drug is cleared.

Mechanism of Action

Detirelix binds competitively to the GnRH receptor on pituitary gonadotropes without activating the receptor. By occupying the binding site, it blocks endogenous GnRH from stimulating the receptor, preventing the intracellular signalling cascade that normally triggers LH and FSH synthesis and release. The resulting fall in LH and FSH diminishes ovarian or testicular steroidogenesis and halts the hormonal support needed for follicular maturation, ovulation, or testosterone production.

What the Research Shows

Human trials in six pre‑menopausal women showed that sub‑cutaneous detirelix reduced serum LH by ~74% within 8 hours and suppressed estradiol, preventing ovulation throughout a 27‑day regimen; LH suppression was reversible within 10–16 days after the final dose. In post‑menopausal volunteers, single sub‑cutaneous doses of 1, 5 and 20 mg produced dose‑dependent reductions in LH (≈40–76%) and modest FSH declines, with LH remaining below baseline for up to 72 hours after the highest dose. A separate study demonstrated that the ovarian response to GnRH antagonism varies with menstrual phase, with consistent pituitary suppression but differing estrogen and progesterone patterns. In free‑ranging African elephants, a single intramuscular dose (4–12 mg) lowered basal LH and testosterone and attenuated GnRH‑stimulated peaks by 50–70% within 48 hours. Pulmonary delivery in awake sheep revealed a half‑life of ~10 hours, mean residence time of 10 hours, and low systemic bioavailability (~10%). An accompanying radioimmunoassay enabled detection of detirelix in plasma down to 0.15 ng/mL, supporting pharmacokinetic monitoring.

Reported Benefits

Research data indicate that detirelix can rapidly and reliably suppress pituitary gonadotropins, providing a tool for short‑term control of reproductive hormone axes. In women, it prevents follicular development and ovulation without systemic side effects, enabling studies of hormone‑dependent processes. In male or male‑like species, it reduces testosterone levels, facilitating investigations of androgen‑mediated functions. Its reversible action allows for timed recovery of normal endocrine cycles after treatment cessation.

Limitations of the Evidence

Evidence is limited to small, short‑duration human cohorts (n ≤ 6) and select animal studies; no large‑scale or long‑term safety data exist. The ovarian response varies with menstrual phase, suggesting unpredictable outcomes in some protocols. Pulmonary administration yields low bioavailability, restricting its utility to systemic delivery routes. Detirelix is not approved for clinical use, and its pharmacology in diverse species remains incompletely characterised.

Safety Considerations

In human volunteers, detirelix caused only mild local skin reactions at injection sites (erythema, pruritus) and no systemic adverse events were reported over the study periods. Post‑menopausal and pre‑menopausal studies did not note additional toxicity. Animal data did not highlight safety concerns, but the limited sample size and short observation windows preclude definitive conclusions about longer‑term or rare adverse effects.

How It Is Administered

Detirelix has been administered subcutaneously in humans (alternating‑day injections of 10 mg for up to 27 days) and intramuscularly in elephants (single 4–12 mg dose). Pulmonary delivery in sheep was achieved via intratracheal instillation or aerosol inhalation, yielding systemic absorption. Formulations are aqueous peptide solutions suitable for injection or aerosolisation.

Routes of Administration

Goals & Uses

• Controlled ovarian stimulation / ARTReproductive MedicineLow
• Treatment of endometriosisGynecologyLow
• Suppression of sex steroids for uterine fibroidsGynecologyLow
• Suppression of testosterone in prostate cancerOncologyLow

Contraindications

• PregnancyPopulationHighPotential fetal risk or insufficient safety data
• Hypersensitivity to GnRH or GnRH analoguesAllergy/immunologyHigh
• History of systemic mast cell disordersImmunologyHigh

Adverse Effects

• Local Injection Site ReactionsDermatologicalCommon
• Histamine-mediated systemic reactionsImmunologicUncommon
• Bone mineral density reductionMusculoskeletalUncommon
• Hypogonadal symptomsEndocrineCommon

Drug Interactions

• QT-prolonging drugsModerate
• Androgen deprivation therapy agentsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with hepatic impairmentOrgan FunctionRelative
• Patients with renal impairmentOrgan ImpairmentRelative

Regulatory Status

• European UnionUnapprovedNo EMA approval or marketing authorization; remained in research phase.
• United StatesUnapprovedInvestigational only; never submitted for or received FDA approval.
• United KingdomUnapprovedNo MHRA approval; not marketed in the UK.

Detirelix never received regulatory approval in any major jurisdiction. It remained an investigational/research compound and was not advanced to NDA/MAA filing. Development was superseded by cleaner GnRH antagonists.

Evidence & Sources

• Pharmacokinetics of detirelix following intratracheal instillation and aerosol inhalation in the unanesthetized awake sheep
  Journal ArticleLowSchreier H, et al.1994-01-01T00:00:00.000000Z
• Effects of GnRH analogues on pituitary-testicular function in free-ranging African elephants (Loxodonta africana)
  Journal ArticleLowBrown JL, et al.1993-01-01T00:00:00.000000Z
• Inhibition of follicular development by a potent antagonistic analog of gonadotropin-releasing hormone (detirelix)
  Journal ArticleLowMarshall LA, et al.1991-01-01T00:00:00.000000Z
• Radioimmunoassay of detirelix ([ N-Ac-D-Nal(2)1,D-p-Cl-Phe2,D-Trp3, D-hArg(Et)6(2),D-Ala10]-luteinizing hormone-releasing hormone) in plasma or serum
  Journal ArticleLowNerenberg C, et al.1988-01-01T00:00:00.000000Z
• Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix)
  Journal ArticleModerateAndreyko JL, et al.1992-01-01T00:00:00.000000Z
• Variable ovarian response to gonadotropin-releasing hormone antagonist-induced gonadotropin deprivation during different phases of the menstrual cycle
  Journal ArticleLowFluker MR, et al.1991-01-01T00:00:00.000000Z

Frequently Asked Questions